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ABSTRACT 28 
Pseudomonas aeruginosa is a major cause of morbidity and mortality in cystic fibrosis 29 
patients. This study compares the antimicrobial susceptibility of 153 P. aeruginosa isolates 30 
from the United Kingdom (UK) (n=58), Belgium (n=44), and Germany (n=51) collected from 31 
120 patients during routine visits over the 2006-2012 period.  MICs were measured by broth 32 
microdilution. Genes encoding extended spectrum β-lactamases (ESBL), metallo-β-33 
lactamases and carbapenemases were detected by PCR. Pulsed Field Gel Electrophoresis 34 
and Multi-Locus Sequence Typing were performed on isolates resistant to ≥ 3 antibiotic 35 
classes among penicillins/cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, 36 
polymyxins.  Based on EUCAST/CLSI breakpoints, susceptibility was ≤ 30%/≤ 40% 37 
(penicillins, ceftazidime, amikacin, ciprofloxacin), 44-48%/48-63% (carbapenems), 72%/72% 38 
(tobramycin), and 92%/78% (colistin) independently of patient’s age. Sixty percent of strains 39 
were multidrug resistant (MDR; European Centre for Disease prevention and Control 40 
criteria). Genes encoding ESBL (most prevalent BEL, PER, GES, VEB, CTX-M, TEM, SHV, 41 
and OXA), metallo β-lactamases (VIM, IMP, NDM), or carbapenemases (OXA-48, KPC) 42 
were not detected. The Liverpool Epidemic Strain (LES) was prevalent in UK isolates only 43 
(75% of MDR isolates).  Four MDR ST958 isolates were found spread over the three 44 
countries. The other MDR clones were evidenced in ≤ 3 isolates and localized in a single 45 
country. A new sequence type (ST2254) was discovered in one MDR isolate in Germany. 46 
Clonal and non-clonal isolates with different susceptibility profiles were found in 21 patients. 47 
Thus, resistance and MDR are highly prevalent in routine isolates from 3 countries, with 48 
carbapenem (meropenem), tobramycin and colistin remaining the most active drugs.  49 
  50 
 51 
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Introduction 52 
Pulmonary infection represents a major cause of morbidity and mortality among cystic 53 
fibrosis (CF) patients (1). These patients are therefore regularly exposed to antibiotics for the 54 
treatment of infectious exacerbations as well as for the prevention of chronic colonization.  55 
Pseudomonas aeruginosa is one of the most prevalent bacterial species, especially in the 56 
adult population (2). It is well known for its genetic plasticity and capacity to accumulate 57 
resistance mechanisms, including acquisition of foreign genetic material (3).  The 58 
percentage of patients colonized by P. aeruginosa has decreased in recent years (2) but, 59 
with improved life expectancy, the absolute number of colonized patients has increased. It 60 
has also been proposed that multidrug resistant (MDR) strains are more frequent in older 61 
patients, primarily due to cumulative exposure to antibiotics (2). A further reason for the 62 
spread of antibiotic resistance in CF patients is the dissemination of MDR clones. The 63 
Liverpool Epidemic Strain (LES), first described in 1996 (4), has proven particularly 64 
successful for acquiring resistance mechanisms over the years (5,6) and for spreading from 65 
the UK to other countries such as Canada, Spain and Australia (7).     66 
In this study, we compared the antimicrobial susceptibility of P. aeruginosa isolated from CF 67 
patients in the United Kingdom (UK), where the MDR LES clone is known to be highly 68 
prevalent (5), with an equivalent number of strains collected in Germany and Belgium, where 69 
no specific survey has been published over the last years. We determined the presence of 70 
co-resistance to unrelated antibiotic classes and its possible association with MDR clones.  71 
We found that resistance was high in the three countries, but not related to the dissemination 72 
of a specific MDR clone in Germany or Belgium.  Carbapenems, tobramycin, and colistin 73 
remain the most active drugs against P. aeruginosa respiratory isolates. Importantly, no 74 
carbapenemases were detected in these strains. 75 
76 
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Materials and methods 77 
 78 
Bacterial isolates  79 
A total of 153 clinical P. aeruginosa isolates were selected at random among those collected 80 
between 2006 and 2012 in 3 CF centers from Belgium (Hôpital des enfants malades Reine 81 
Fabiola/Erasme Hospital, n = 44); Germany (University Hospital of Münster, n = 51) and UK 82 
(Queen’s University of Belfast, n = 58) during routine visits. The details on the collection are 83 
shown in Table 1. When successive strains were collected from a single patient, only those 84 
collected at the first occasion were considered.  Nevertheless, more than one isolate were 85 
analyzed for some patients based on differences in their phenotypic appearance (see Figure 86 
S1 in supplemental material).  87 
 88 
Antibiotics 89 
The following antibiotics were obtained as microbiological standards (with abbreviations and 90 
potencies shown in parentheses): amikacin disulfate (AMK; 74.80%), colistin sulfate (CST; 91 
79.64%); piperacillin sodium (PIP; 94.20%), and ticarcillin disodium salt (TIC; 85.25%) from 92 
Sigma-Aldrich, St. Louis, MO; ciprofloxacin (CIP; 85.00%) from Bayer, Leverkusen, 93 
Germany; and tobramycin (TOB; 100%) from Teva, Wilrijk, Belgium. The remaining 94 
antibiotics were obtained as the corresponding branded product in Belgium for intravenous 95 
use and complying with the provisions of the European Pharmacopoeia with respect to 96 
content in active agent: ceftazidime as Glazidim® (CAZ; 88.20%) from GlaxoSmithKline, 97 
Genval, Belgium; imipenem as Tienam® [also containing cilastatin which does not have any 98 
antibacterial activity] (IPM; 45.60%) from MSD, Brussels, Belgium; meropenem as 99 
Meronem® (MEM; 74.00%) from AstraZeneca, Brussels, Belgium; piperacillin-tazobactam 100 
as Tazocin® (TZP; 97.00%) from Wyeth, Louvain-La-Neuve, Belgium [now part of Pfizer]. 101 
 102 
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Susceptibility testing 103 
Minimal Inhibitory Concentrations (MIC) were determined by microdilution in cation-adjusted 104 
Mueller-Hinton broth following CLSI (Clinical and Laboratory Standards Institute) 105 
recommendations, using P. aeruginosa ATCC 27853 as quality control strain (8). 106 
Susceptibility was assessed according to the interpretive criteria of both the European 107 
Committee on Antimicrobial Susceptibility Testing (EUCAST) (9) and the CLSI (8).  Isolates 108 
were considered as multi-drug resistant (MDR) if resistant to at least three antibiotic classes 109 
among those tested (penicillins/cephalosporins, carbapenems, fluoroquinolones, 110 
aminoglycosides and polymyxins), according to ECDC (European Centre for Disease 111 
Prevention and Control) criteria (10).  112 
 113 
Screening for extended-spectrum β-lactamases (ESBL) and carbapenemases 114 
For all isolates (n=51) showing MICs > 8 mg/L for ceftazidime and meropenem, blaTEM, 115 
blaSHV, blaCTX-M (groups 1, 2 and 9), blaVIM, blaIMP, blaKPC, and blaNDM gene families were 116 
detected by real-time multiplex PCR, using group-specific primers ([11-13] and references 117 
cited therein). Other genes encoding OXA (1,2,9,10,18,20,23,24,30,48, 58,198), BEL (1 to 118 
3), PER (1 to 5, and 7), GES (1 to 18), and VEB (1 to 7) enzymes were also detected by 119 
multiplex PCR. 120 
 121 
Molecular typing 122 
All MDR isolates in the collection showing co-resistance to penicillins and/or cephalosporins 123 
and two other classes (n=56) were characterized by Pulsed-Field Gel Electrophoresis 124 
(PFGE) analysis (14). In addition, 42 pairs of isolates collected simultaneously and in the 125 
same sample from 21 patients (see Figure S1) but differing in their susceptibility profile to at 126 
least one class of antibiotics were also genotyped by PFGE to determine their genetic 127 
relatedness. The pulsotype classification criteria designated a pulsotype by one or two 128 
letters including patterns showing zero to six DNA fragments differences (14).  An epidemic 129 
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pulsotype was defined as a pulsotype recovered from ≥ 2 patients while a sporadic 130 
pulsotype was recovered only once. 131 
Multilocus sequence typing (MLST) was performed on a representative strain of epidemic 132 
pulsotypes detected in ≥ 3 strains, as previously described (15). The reference LES B58 133 
strain (4) was used as control. MLST data were uploaded to the P. aeruginosa MLST 134 
Database (http://pubmlst.org/paeruginosa) for allele type and sequence type (ST) 135 
assignments (16).  136 
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Results  137 
MIC distributions 138 
Table 2 shows the MIC distribution for 9 antipseudomonal drugs against 153 isolates 139 
collected from 120 CF patients originating from three different countries over the 2006-2012 140 
period, together with the percentage susceptible and resistant based on both EUCAST and 141 
CLSI interpretive criteria.  The corresponding MIC cumulative distributions are illustrated in 142 
Figure S2. Resistance was high in this collection. Using the EUCAST or the CLSI "R" 143 
breakpoints, respectively, full resistant isolates were ≥71% or ≥54% for penicillins (ticarcillin, 144 
piperacillin, piperacillin-tazobactam), 69% or 59% for ceftazidime, 61% or 46% for amikacin, 145 
56% or 27% for ciprofloxacin, ≥20% for carbapenems, and 28 or 16% for tobramycin. Full 146 
resistance to colistin was noted for only 8% of the isolates. Strains resistant to ceftazidime 147 
and meropenem were screened for the expression of frequent ESBLs, metallo β-148 
lactamases, and carbapenemases, which returned negative results. 149 
 150 
Cross- or co-resistance 151 
Cross- or co-resistance was examined among pairs of antibiotics.  Cross-resistance is 152 
defined as a single resistance mechanism that confers resistance to antimicrobial molecules 153 
with a similar mechanism(s) of action. It thus describes resistance to an entire class of 154 
antibiotics, or to different classes of agents with overlapping drug targets, or to different 155 
classes of antibiotics that are substrates for the same broad-spectrum efflux system. Co-156 
resistance rather refers to the presence of different mechanisms of resistance in the same 157 
bacterial isolate, and is thus necessarily confers resistance to unrelated antibiotic classes 158 
(17). Ninety-four strains were considered as MDR according the ECDC (10). The right upper 159 
part of Table 3 shows the percentage of strains showing cross- or co-resistance to pairs of 160 
antibiotics according to EUCAST criteria. About 2/3 of the strains were resistant to both 161 
penicillins and ceftazidime and more than 40%, to penicillins and ceftazidime together with 162 
amikacin or ciprofloxacin.  Co-resistance between any studied drug and tobramycin, 163 
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meropenem, and colistin was lower than 28%, 20% and 8%, respectively.  Of note, only 4 164 
strains in the whole collection were co-resistant to meropenem, tobramycin, and colistin 165 
(Figure S3). 166 
The left lower part of Table 3 shows the correlation coefficient between the individual MIC for 167 
each pair of antibiotics, with the corresponding multivariate analysis presented in details as 168 
supplementary Figure S4.  The highest degrees of correlation (> 0.75) between individual 169 
MICs were observed for ticarcillin vs. ceftazidime, piperacillin vs. piperacillin-tazobactam, 170 
ceftazidime vs. piperacillin-(tazobactam), imipenem vs. meropenem, and amikacin vs. 171 
tobramycin, suggesting common mechanisms of resistance between these pairs of 172 
antibiotics.  Yet, differences in the intrinsic potency were nevertheless observed between 173 
these pairs of drugs throughout the collection; they are illustrated in Figure S4 and 174 
associated Table B: tazobactam reduced the MIC of piperacillin by a factor of 1.5 dilution, 175 
while ceftazidime MICs were 0.5 and 1 dilution lower than those of ticarcillin and piperacillin 176 
respectively, and similar to those of piperacillin-tazobactam. Meropenem MICs were 1 177 
dilution lower than those of imipenem, and tobramycin MICs were 3 dilutions lower than 178 
those of amikacin.  179 
 180 
Typing of MDR isolates 181 
Among the 94 MDR isolates, most were resistant to penicillins and/or cephalosporins. Only 182 
those showing resistance to at least 2 other classes (n = 56) were characterized by PFGE 183 
analysis. A high genetic diversity was observed, with 19 sporadic pulsotypes and 9 epidemic 184 
pulsotypes (Table 4). With the exception of pulsotype YY recovered for 1 or 2 isolates in the 185 
three countries, each epidemic pulsotype remained localized in a single country.  The CA 186 
epidemic pulsotype found in 3/4 of the UK isolates corresponded to the pulsotype of the LES 187 
clone.  MLST analysis of epidemic pulsotypes CA, H and YY showed ST146, ST2254 (new 188 
ST) and ST958, respectively (data not shown).   189 
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PFGE analysis was also performed on 42 isolates collected as pairs from 21 patients and 190 
displaying different susceptibility profiles (Table S1). In twelve patients, the pair of 191 
P. aeruginosa isolates had the same pulsotype, while the 9 other patients had isolates with 192 
different pulsotypes. 193 
 194 
Analysis per country or age group 195 
Because of the genetic diversity observed between countries, we then examined the 196 
distribution of susceptible, intermediate (when applicable) and resistant isolates classified 197 
based on the country where they were collected (Figure 1). Susceptibility rates differed 198 
among countries, with lower resistance in Belgium (significant for all antibiotics except 199 
ticarcillin and ciprofloxacin) and higher resistance in Germany and UK (significant for 200 
piperacillin-tazobactam in Germany and for imipenem, ciprofloxacin, and colistin in UK) as 201 
compared to the mean value for the whole collection. There was no significant correlation 202 
between the patient’s age when the isolate was collected and the number of antibiotic 203 
classes to which the isolate was resistant (Figure S5).   204 
205 
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Discussion 206 
In this study, we examined antibiotic susceptibility of a collection of P. aeruginosa isolated 207 
from CF patients in three Northern European countries during routine examination, which 208 
provides a broader view than the majority of previous surveys that have focused on a single 209 
country (18-20) or a single center (21-23).  A key observation is that resistance rates were 210 
high in this population, confirming previous studies with CF patients (2), and notably 211 
A.9.much higher than that which has been reported for isolates collected in Northern 212 
European from intensive care units (24-26). Resistance rates were also higher than those 213 
previously reported for strains from CF patients in a German survey from the University of 214 
Würzburg except for tobramycin (27; collection in 2006), or in a multicentric study in the UK, 215 
except for meropenem and ciprofloxacin (28; collection in 2000).  Moreover, a high degree of 216 
cross- or co-resistance among antibiotics was observed, which is important from both a 217 
pharmacological and clinical perspective.  218 
 219 
From a pharmacological perspective, we noticed, as expected, significant correlations 220 
between MIC values for antibiotics belonging to the same or similar classes (penicillins and 221 
ceftazidime or other penicillins, imipenem and meropenem, and amikacin and tobramycin), 222 
but with systematic differences in the potency of each antibiotic within these pairs (see 223 
Figure S3 and related Table B). Focusing on β-lactams, the impact of tazobactam on 224 
piperacillin activity was modest, but of the same order of magnitude as that observed on MIC 225 
distribution for wild-type strains reported by EUCAST (29), probably denoting the inhibition 226 
by tazobactam of the low basal levels of AmpC produced by the wild-type strains (30,31). 227 
Likewise a higher potency of ceftazidime compared to  penicillins and of meropenem 228 
compared to imipenem is reported in wild-type EUCAST distributions (29).  Thus differences 229 
in potency among these pairs of drugs in our collection are likely to reflect differences in 230 
intrinsic activity rather than in vulnerability to resistance mechanisms.  Remarkably no 231 
carbapenemase production was apparent in this collection. A same finding was reported in 232 
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two recent reports studying P. aeruginosa collected over the same period of time as those 233 
examined here.  The first of these studies was performed in Australia and examined 234 
successively a collection of 662 carbapenem-resistant isolates assembled in 2007-2009 235 
from diverse CF centers and of 517 isolates collected in a single CF center in 2011 (32). The 236 
second study was performed in Brazil and analyzed isolates from 75 patients collected in 237 
2010-2011 (19).  To the opposite, carbapenemases have been detected in 63 out of 217 238 
P. aeruginosa collected from CF patients in China (22). The prevalence of carbapenemase 239 
genes could, however, be different in other bacteria infecting CF patients, but there is no 240 
large survey published so far in other Gram-negative species (33,34).  241 
Thus, carbapenem resistance in CF European isolates is probably primarily mediated by the 242 
combined effect of AmpC and of a reduced accumulation (porin mutations and/or increased 243 
efflux) (35; Chalhoub et al, submitted for publication].  Of note, however, carbapenem 244 
resistance has previously been described in the LES clone (5) but the underlying 245 
mechanism(s) have not been investigated to date. For aminoglycosides, the higher potency 246 
of tobramycin over amikacin in our collection also reflects what is observed in MIC 247 
distributions of wild-type strains assembled by EUCAST (29).  Tobramycin has been 248 
described as a poorer substrate than amikacin for the efflux pump MexXY-OprM considered 249 
as responsible for natural and adaptative resistance to aminoglycosides in P. aeruginosa 250 
(36,37).   251 
Considering our findings from a clinical perspective, a high degree of cross-resistance was 252 
observed between penicillins and ceftazidime, which was expected. However, a high degree 253 
of co-resistance was also apparent between these antibiotics and both ciprofloxacin and 254 
amikacin, resulting in 60 % of the isolates being categorized as multidrug resistant. In 255 
contrast, meropenem, and colistin, and to a lesser extent, tobramycin, were active against a 256 
large fraction of the isolates with few strains co-resistant to these three antibiotics. 257 
Tobramycin and colistin by inhalation are often considered as first line for the eradication of 258 
early P. aeruginosa infection and tobramycin, also for chronic therapies (38-40).  High 259 
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concentrations delivered by this route of administration may help to overcome resistance 260 
(41,42). 261 
 262 
We also noticed an important genetic diversity among multi-resistant isolates collected in 263 
Belgium and Germany while those collected in the UK belong in majority to the Liverpool 264 
Epidemic Strain (LES) clone. Global studies of P. aeruginosa population structure concluded 265 
that CF isolates present a high genetic diversity but nevertheless belong to a ‘core lineage’ 266 
ubiquitous in the natural environment (43), which is highly suggestive of a direct colonization 267 
of the patients from the environment.  However, a series of epidemic clones have been 268 
described (7) among which the LES (4) representing 18 of the 24 MDR isolates collected in 269 
the UK in our study, and the ST17 (7), which differs by only 1 nucleotide from the ST958 270 
found in the three countries investigated here. The new ST2254 we described was distinct 271 
from ST146 (LES clone, 5 alleles difference) and ST958 or ST17 (6 alleles difference). 272 
 273 
We observed that a single patient can be colonized by different strains and, conversely, that 274 
clonally-related strains isolated at the same time from a single patient can harbor diverse 275 
susceptibility profiles. This could be a consequence of the previously described phenotypic 276 
variability among isolates with the same colony morphotype and being part of a single clonal 277 
lineage (44,45), as well as of recombination occurring in vivo and generating phenotypic and 278 
genetic diversification (46,47). 279 
 280 
Although limited, differences in resistance rates between Belgium and the other two other 281 
countries are raising questions about segmentation of clone distribution. For strains collected 282 
in the UK, higher resistance is clearly related to the high prevalence of the LES clone, which 283 
has been described as exhibiting a large proportion of MDR isolates (5).  Of interest, we 284 
observed different resistance profiles within this clone, which is coherent with the previously 285 
described phenotypic variability among LES isolates (6).  The ST958 represented in the 286 
three countries is also found among the MDR clonal complexes (7). In the German 287 
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collection, higher resistance is essentially related to the presence of more sporadic MDR 288 
clones than in the two other countries. We cannot exclude differences in therapeutic 289 
management of patients among these three centers that may influence resistance selection 290 
(48) but this specific aspect was not within the scope of our study.  291 
 292 
Resistance rates were not higher in the older population than in children/young adults. The 293 
interpretation of these data need to be cautious because (a) we did not follow the evolution 294 
of susceptibility over time in single patients and (b) we do not know the age of first 295 
colonization for each patient.  With this limitation in mind, the fact that MDR isolates could be 296 
found in young people and susceptible isolates in adults may suggest that resistance 297 
depends on the initial susceptibility of the infecting strain. A link between emergence of 298 
resistance and early antibiotic use in CF patients is still controversial, even though 299 
underlined in the last report of the Cystic Fibrosis Foundation (2).  A recent study in Australia 300 
showed that multiresistance in children is correlated with duration of intravenous antibiotic 301 
treatment, which was not the case for adults (18). A correlation with antibiotic usage 302 
irrespective of patient’s age (49) or with time after colonization (6) has also been proposed.  303 
In contrast, other studies following the evolution of antibiotic susceptibility in successive 304 
isogenic isolates from a single patient suggest either that resistance can occur sporadically 305 
(50) or without correlation with the time of isolation (51). In these cases, the presence of 306 
mutator variants seems to predetermine the risk of developing resistance over time (6).   307 
 308 
Our study has a number of limitations, primarily linked to the fact that samples collected 309 
during periodic routine examinations may not correspond to the first isolates of 310 
P. aeruginosa infections in these patients.  Moreover, as we did not have the history of 311 
antibiotic use in these patients, we could not determine if there was a potential link between 312 
antibiotic usage and subsequent development of resistance.  Nevertheless, this collection 313 
reflects the situation CF clinicians face daily, where they have to select antibiotics based on 314 
susceptibility testing performed on current isolates. In this context, our data may lead to 315 
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three clinically-meaningful conclusions.  First, susceptibility testing is important to perform 316 
even in newly infected patients, because they can be colonized very early by MDR clones.  317 
Second, these tests should be performed on more than one colony (especially if different 318 
phenotypes are evidenced on culture plates), because of potential population heterogeneity 319 
with respect to susceptibility profiles (52).  Third, prudent use of highly active drugs should 320 
be promoted in order to preserve their efficacy.  This implies the use of optimized doses if 321 
administered by conventional routes or administration by inhalation to insure high local 322 
concentrations that could minimize the risk of selection of resistance.   323 
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 532 
Table 1:  P. aeruginosa collection (2006-2012) 533 
Country Number of isolates Number of patients Period of sampling 
Belgium 44 38 2010 
Germany 51 36 2012 
United Kingdom 58 46 2006-2009 
Total 153 120  
 534 
 535 
  536 
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Table 2: MIC distributions for antipseudomonal antibiotics and corresponding percentage of susceptibility according to EUCAST or 537 
CLSI breakpoints 538 
Antibiotic MIC distribution (mg/L) 
Susceptibility according to 
EUCAST a CLSI b 
min max MIC50 MIC90 % S % I %R % S %I %R 
Ticarcillin (TIC) 1 >512 128 >512 16 NA 84 16 23 61 
Piperacillin (PIP) 0.5 >512 256 >512 24 NA 76 24 15 61 
Piperacillin-
tazobactam (TZP) 0.5 >512 128 512 29 NA 71 29 17 54 
Ceftazidime (CAZ) 1 >512 64 512 31 NA 69 31 10 59 
Imipenem (IPM) 0.25 128 4 32 48 19 33 48 19 33 
Meropenem (MEM) 0.032 256 2 16 44 36 20 63 17 20 
Amikacin (AMK) 1 >512 32 128 22 17 61 39 15 46 
Tobramycin (TOB) 0.064 >512 2 16 72 NA 28 72 12 16 
Ciprofloxacin (CIP) 0.064 64 1 8 24 20 56 44 29 27 
Colistin (CST) 0.25 >512 1 4 92 NA 8 78 14 8 
a  EUCAST breakpoints (NA: not applicable [no I category]): TIC S≤16 R>16; PIP S≤16 R>16; TZP S≤16 R>16; CAZ S≤8 R>8; IPM S≤4 
R>8; MEM S≤ 2 R>8; AMK S≤ 8 R>16; TOB S≤ 4 R>4; CIP S≤ 0.5 R>1; CST S≤ 4 R>4. 
b CLSI breakpoints: TIC S≤16, I=32-64, R≥128; PIP S≤16, I=32-64, R≥128; TZP S≤16, I=32-64, R≥128; CAZ S≤8, I=16, R≥32; IPM S≤4, 
I=8, R≥16; MEM S≤4, I=8, R≥16; CIP S≤1, I=2, R≥4; AMK S≤16, I=32, R≥64; TOB S≤4, I=8, R≥16; CST S≤2, I=4, R≥8. 
S: susceptible; I: intermediate; R: resistant 
 539 
 540 
 541 
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Table 3: Percentage of co-resistance among pairs of antibiotics and multivariate correlation between MIC values of each pair of 543 
antibiotics for individual strains. 544 
Above the diagonal, figures correspond to the percentage of isolates categorized as resistant to the two antibiotics (row/column) using 545 
EUCAST breakpoints.  Values highlighted in bold indicate combinations for which resistance is higher than 30 %. 546 
The numbers below the diagonal correspond to the correlation coefficient between individual MIC values for each pairs of antibiotics. Values 547 
higher than 0.75 are highlighted in bold characters.  See Table 2 for abbreviations of antibiotics and Figure S4 for the details of this analysis. 548 
 549 
 Percentage of cross- or co-resistance 
r  v
a l u
e  (
m u
l t i v
a r
i a t
e  c
o r
r e
l a t
i o n
)  
TIC 68 71 69 31 20 54 25 48 8 
0.78 CAZ 68 65 29 20 48 24 42 7 
0.72 0.88 PIP 71 31 20 52 24 45 7 
0.73 0.86 0.94 TZP 30 20 50 24 42 7 
0.53 0.47 0.47 0.45 IPM 16 24 12 24 4 
0.66 0.55 0.48 0.54 0.80 MEM 14 7 18 3 
0.37 0.46 0.40 0.36 0.34 0.26 AMK 28 38 8 
0.26 0.40 0.31 0.28 0.29 0.17 0.90 TOB 22 5 
0.26 0.30 0.27 0.28 0.39 0.43 0.31 0.31 CIP 6 
0.18 0.16 0.14 0.11 0.13 0.04 0.32 0.34 0.01 CST 
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Table 4: Distribution of pulsotypes among the MDR P. aeruginosa clinical isolates 550 
Country Number of MDR strains 
Number of pulsotypes  Number of strains in epidemic pulsotype 
Sporadic Epidemic  CAa CK CM CD H WW YI CJ YY 
Belgium 10 3 4  0 0 2 2 0 2 0 0 1 
Germany 22 11 5  0 2 0 0 3 0 2 2 2 
United Kingdom 24 5 2  18 0 0 0 0 0 0 0 1 
a CA pulsotype corresponds to the LES epidemic clone pulsotype 551 
 552 
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Figure 1: Comparison of the percentage of antibiotic resistance in the collection based on 553 
the country of origin of the strain (Belgium (BE): n=44; Germany (DE): n=51; United 554 
Kingdom (UK): n=58).  Statistical analysis: Chi Square test (p values indicated after the 555 
name of the antibiotic); Analysis of means of proportions with α level of 0.05: * denotes a 556 
value below the mean and #, above the mean. 557 
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